← Verrica Pharmaceuticals Inc.
Signed Aug 3, 2026
| Tranche | Size | Matures | Margin |
|---|---|---|---|
| Term Loan | n/a | Dec 2030 | 750 bps |
Priced over SOFR, floor 450 bps (Delayed draw term loan).
| Level | Condition | Margin | Unused fee |
|---|---|---|---|
| Level After First Rate Step-Down | after First Rate Step-Down Condition | 750 bps | n/a |
Lenders: PD JOINT HOLDINGS, LLC SERIES 2016-B
Equity cure available.
Tested as of the last day of each Fiscal Year of Borrower, Borrower’s revenue from YCANTH for each such Fiscal Year shall be equal to at least [***]% of the amount of Borrower’s projected revenue from YCANTH for such Fiscal Year as set forth in the Board-Approved Budget for that same Fiscal Year.Read the filing on sec.gov ↗
Subject to Section 5.17, tested monthly and applicable at all times, the Borrower shall not permit Liquidity to be less than Five Million Dollars ($5,000,000).Read the filing on sec.gov ↗
Make Capital Expenditures in the aggregate in any Fiscal Year of Borrower in excess of the sum of (i) the amount of Capital Expenditures in the Board-Approved Budget for such Fiscal Year, plus (ii) One Million Dollars ($1,000,000).Read the filing on sec.gov ↗
No amendments on file yet.
Email [email protected].